Accumulating evidence strongly suggests that the alterations within KRAS, p53, CDKN2A and SMAD4 are frequently detected in pancreatic cancer tissues, and contribute to the genesis and/or maintenance of their advanced phenotypes including GEM resistance [5]. The gene discussed is TP53; the disease is familial pancreatic carcinoma.